An immunohistochemical assessment of cathepsin D in gastric carcinoma: Its impact on clinical prognosis

Cancer

Volumn 80, Issue 2, 1997, Pages 179-187

  Allgayer, Heike ^a   Babic, Rudolf ^b   Grützner, Klaus Uwe ^a   Beyer, Bianca C M ^a   Tarabichi, Anwar ^a   Schildberg, Friedrich Wilhelm ^a   Heiss, Markus Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institute of Pathology and Cytology   (Germany)

Author keywords

Cathepsin D; Gastric carcinoma; Oncology; Prognosis; Tumor associated proteolysis; uPA system

Indexed keywords

CATHEPSIN D; UROKINASE;

ADULT; AGED; ARTICLE; CANCER RISK; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; QUANTITATIVE DIAGNOSIS; SCORING SYSTEM; STOMACH CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CATHEPSIN D; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SERINE PROTEINASE INHIBITORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030930519     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970715)80:2<179::AID-CNCR2>3.0.CO;2-P     Document Type: Article

References (46)

1. Bond JS. Overview on protease classes, clans, and families. Proceedings, AACR Special Conference, Proteases and Protease Inhibitors, Panama City, Florida, March 1-5, 1996.
2. Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986;315:1650-9.
3. Schwartz MK. Tissue cathepsins as tumor markersn. Clin Chim Acta 1995;237:67-78.
4. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast carcinoma cell lines. Cell 1980;20:353-62.
5. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast carcinoma. N Engl J Med 1990;322:297-302.
6. Eng Tan P, Benz CC, Dollbaum C, Moore DH II, Edgerton SM, Zava DT, et al. Prognostic value of cathepsin D expression in breast carcinoma: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 1994; 5:329-36.
7. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. Am J Pathol 1992;141:1003-12.
8. Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P, Battifora H. Prognostic significance of immunohistochemical analysis of Cathepsin D in low-stage breast carcinoma. Carcinoma 1993;71:2756-63.
9. Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast carcinoma. Carcinoma 1990;65:265-71.
10. Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, et al. Clinical significance of cathepsin D assay in breast carcinoma tissues. J Surg Oncol 1995;60:221-6.
11. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, et al. Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast carcinoma. EurJ Carcinoma 1995; 31A:671-7.
12. Aaltonen M, Lipponen P, Kosma VM, Aaltomaa S, Syrjänen K. Prognostic value of cathepsin D expression in female breast carcinoma. Anticarcinoma Res 1995;15:1033-8.
13. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, et al. Association between high concentrations of Mr 52.000 Cathepsin D and poor prognosis in primary human breast carcinoma. Carcinoma Res 1989;49:6008-14.
14. Duffy MJ, Reilly D, Brouillet JP, McDermott EW, Faul C, O'Higgins N, et al. Cathepsin D concentration in breast carcinoma cytosols; correlation with disease-free interval and overall survival. Clin Chem 1992;38:2114-6.
15. Foekens JA, van Putten WL, Henk J, Portengen H, de Konig H, Bruno T, et al. Diagnostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 1993;11:899-908.
16. Westley B, Rochefort H. Estradiol induced protein in the MCF-7 human breast carcinoma cell line. Biophys Res Commun 1979;90:410-6.
17. Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar G, Rochefort H. Increased secretion, altered processing and glycosylation of procathepsin D in mammary carcinoma cells. Carcinoma Res 1989;49:3904-9.
18. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991;266:5147-52.
19. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992;6(Suppl 4):3-26.
20. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991;115:1107-12.
21. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993;15:105-11.
22. Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H. Autocrine growth stimulation of the MCF 7 breast carcinoma cells by the estrogen-regulated 52K protein. Endocrinology 1986;118:1537-45.
23. Maurizi M, Almadori G, Cadoni G, Scambia G, Ottaviani F, Ferrandina G, et al. Cathepsin D concentration in primary laryngeal carcinoma: correlation with clinicopathological parameters, EGFR status and prognosis. Int J Carcinoma 1996;69:105-9.
24. Berns EMJJ, Klijn JGM, Schmitt M, Henzen-Logmans SC, van der Berg MEL, Jänicke F, et al. Occurrence and interrelationships of urokinase-type plasminogen activator inhibitor-1 and cathepsin D in human ovarian tissues. Proc Am Assoc Carcinoma Res 1994;35:69.
25. Metaye T, Millet C, Kraimps J, Aubouin B, Barbier J, Begon F. Estrogen receptors and cathepsin D in human thyroid tissue. Carcinoma 1993;72:1991-6.
26. Adenis A, Huet G, Zerimech F, Hecquet B, Balduyck M, Beyrat JP. Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Carcinoma Lett 1995;96:267-75.
27. Leto G, Tumminello FM, Russo A, Pizzolanti G, Bazan V, Gebbia N. Cathepsin D activity levels in colorectal carcinoma: correlation with cathepsin B and L and other biological and clinical parameters. Int J Oncol 1994;5:509-15.
28. Tumminello FM, Gebbia N, Pizzolanti G, Russo A, Bazan V, Leto G. Cathepsin D content in colorectal carcinoma. Oncology 1995;52:237-42.
29. Saku T, Sakai H, Tsuda N, Okabe H, Kato Y, Yamamoto K. Cathepsin D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. Gut 1990;31:1250-5.
30. Matsuo K, Kobayashi I, Tsukuba T, Kiyoshima T, Ishibashi Y, Miyoshi A, et al. Immunohistochemical localization of cathepsin D and E in human gastric carcinoma: a possible correlation with local invasive and metastatic activities of carcinoma cells. Hum Pathol 1996;27:184-90.
31. Graeff H, Harbeck N, Fache O, Wilhelm O, Jänicke F, Schmitt M. Prognostic impact and clinical relevance of tumor-associated proteases in breast carcinoma. Fibrinolysis 1992; 6(Suppl 4):45-53.
32. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Carcinoma Res 1994;54:120-3.
33. Heiss MM, Babic R, Allgayer H, Grützner KU, Jauch KW, Löhrs U, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric carcinoma defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084-93.
34. Heiss MM, Babic R, Allgayer H, Grützner KU, Jauch KW, Löhrs U, et al. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumor differentiation in gastric carcinoma. Eur J Surg Oncol 1996;22: 74-7.
35. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hoefler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast carcinoma. Breast Carcinoma Res Treat 1993;24:195-208.
36. r 52.000 glycoprotein and their use in MCF7 cells. Carcinoma Res 1985;45:709-16.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
38. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Carcinoma 1977;37:1-39.
39. Cox DR. Regression models and life tables. J Stat Soc (B) 1972;34:187-220.
40. Dixon WJ, Brown MB, Engelman L, Frane JW, Hill MA, Jennrich RI, et al. BMDP statistical software. Berkeley:University of California Press, 1985.
41. r 52.000 Cathepsin D secreted by breast carcinoma cells. Carcinoma Res 1988;48:3688-92.
42. Theodoropoulos GE, Lazaris AC, Panoussopoulos D, Davaris P, Golematis BC. Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarcinoma. J Surg Oncol 1995;58:176-83.
43. Roger P, Montcourrier P, Maudelonde T, Brouillet JP, Pages A, Laffargue F, et al. Cathepsin D immunostaining in paraffin-embedded breast carcinoma cells and macrophages: correlation with cytosolic assay. Hum Pathol 1994;25:863-71.
44. Valentini AM, Pirrelli M, Armentano R, Caruso ML. The immunohistochemical expression of cathepsin D in colorectal carcinoma. Anticarcinoma Res 1996;16:77-80.
45. Nazeer T, Malfetano JH, Rosano TG, Ross JS. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Am J Clin Pathol 1992;97:764-9.
46. Laurén R. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-4.